Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

GSK PLC (NYSE:GSK), also known as Glaxo-Smith Kline, is a top biotech company focused on advancing promising treatments for various cancers. Like the other players on this list, GSK does have ...

GSK Plc’s RSV vaccine has been approved for wider use in adults in Europe in a boost for the UK company’s blockbuster shot. The European Commission recommended GSK’s Arexvy for adults aged ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Pharmaceutical giant GlaxoSmithKline (GSK) and rival drug manufacturers, including Sanofi, Pfizer and Boehringer Ingelheim, have won the right to an appeal hearing by the Delaware Supreme Court ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The notice specifically concerns the acquisition of the Horlicks brand in India from GSK for ₹3,045 crore. Additionally, other GSKCH brands such as Boost, Maltova, and Viva were also added to ...